NCT03205423View on ClinicalTrials.gov

Medication Development for Opioid and Alcohol Abuse

PHASE2CompletedINTERVENTIONAL

Enrollment

Participants

Timeline

Start Date

August 1, 2017

Primary Completion Date

June 30, 2021

Study Completion Date

December 30, 2021

Conditions

Opioid-use DisorderAlcohol Use Disorder

Interventions

DRUG

Gabapentin

Maintenance medication under investigation for its ability to alter the subjective and reinforcing effects of experimenter-administered doses of oxycodone and alcohol.

Trial Locations (1)

10032

New York State Psychiatric Institute in the Division on Substance Use Disorders, New York

All Listed Sponsors

lead

New York State Psychiatric Institute

OTHER

NCT03205423 - Medication Development for Opioid and Alcohol Abuse | Biotech Hunter | Biotech Hunter